Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $201.8 million.

  • Editas Medicine's Liabilities and Shareholders Equity fell 38.41% to $201.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 38.40%. This contributed to the annual value of $341.6 million for FY2024, which is 31.57% down from last year.
  • Latest data reveals that Editas Medicine reported Liabilities and Shareholders Equity of $201.8 million as of Q3 2025, which was down 4.19% from $210.6 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Liabilities and Shareholders Equity peaked at $780.3 million during Q1 2021, and registered a low of $201.8 million during Q3 2025.
  • For the 3-year period, Editas Medicine's Liabilities and Shareholders Equity averaged around $380.0 million, with its median value being $384.8 million (2024).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 67.18% in 2021, then tumbled by 45.28% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Liabilities and Shareholders Equity stood at $677.5 million in 2021, then decreased by 24.08% to $514.3 million in 2022, then dropped by 2.95% to $499.2 million in 2023, then tumbled by 31.57% to $341.6 million in 2024, then crashed by 38.41% to $201.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $201.8 million for Q3 2025, versus $210.6 million for Q2 2025 and $263.7 million for Q1 2025.